NCT02659397 - A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Hyperlipidemia

Interventions

DRUG

ETC-1002

Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)

DRUG

Atorvastatin

Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)

DRUG

Placebo

Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)

Trial Locations (19)

22203

Arlington

23294

Richmond

24501

Lynchburg

32127

Port Orange

32216

Jacksonville

33126

Miami

33765

Clearwater

40213

Louisville

57701

Rapid City

60607

Chicago

62711

Springfield

75006

Carrollton

83642

Boise

84088

West Jordan

90057

Los Angeles

91324

Northridge

92801

Anaheim

98057

Renton

08009

Berlin